These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 33907270)

  • 1. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of
    Lin H; Wang J; Shi Q; Wu M
    PeerJ; 2024; 12():e17338. PubMed ID: 38708353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma.
    Zhou Y; Xu M; Zhao K; Liu B
    J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyroptosis-related long-noncoding RNA signature predicting survival and immunotherapy efficacy in patients with lung squamous cell carcinoma.
    Zhan X; Li J; Ding Y; Zhou F; Zeng R; Lei L; Zhang Y; Feng A; Qu Y; Yang Z
    Clin Exp Med; 2024 Jul; 24(1):145. PubMed ID: 38960987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
    Huang G; Zhang J; Gong L; Huang Y; Liu D
    BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
    BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the Lung Squamous Cell Carcinoma Diagnosis and Prognosis Markers by Unique DNA Methylation and Gene Expression Profiles.
    Wang W; Wang S; Chu X; Liu H; Xiang M
    J Comput Biol; 2020 Jul; 27(7):1041-1054. PubMed ID: 31710242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
    BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma.
    Zhai W; Chen S; Duan F; Wang J; Zhao Z; Lin Y; Rao B; Wang Y; Zheng L; Long H
    Cancer Med; 2023 Feb; 12(4):4968-4980. PubMed ID: 36056909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network.
    Li R; Yang YE; Jin J; Zhang MY; Liu X; Liu XX; Yin YH; Qu YQ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3246-3258. PubMed ID: 31364871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.